Introduction {#s1}
============

The human nasopharynx is the main reservoir for pneumococci. The bacteria which adhere to pharyngeal epithelial cells through epithelial receptor molecules may be acquired very early in life [@pone.0085001-Darboe1], [@pone.0085001-Hill1], and in most children the pneumococcus is present in the nasopharynx at some point in the first few years of life [@pone.0085001-Gray1]. Carriage is generally higher in developing countries and among economically deprived populations [@pone.0085001-Huang1], [@pone.0085001-RegevYochay1]. The prevalence of carriage might also vary between developing countries. In one study, Abdullahi et al suggested that colonisation prevalence in East and Southern Africa is substantially lower than in the Gambia [@pone.0085001-Abdullahi1]. High prevalence have however been reported in Ethiopia and Mozambique.

Carriage is a prerequisite for disease [@pone.0085001-Gray1], [@pone.0085001-Bogaert1] and because it is much more common than a disease outcome, it may be a valuable measure of the efficacy of new pneumococcal vaccines [@pone.0085001-RintaKokko1]. The relation between carriage and disease was first demonstrated in a cohort of infants [@pone.0085001-Gray2]. Subsequent studies showed that carriage is a risk factor for acute and recurrent otitis media in children [@pone.0085001-Faden1], [@pone.0085001-Syrjanen1]. Other studies have shown that bacterial carriage densities may be related to the risk of disease in adults and children [@pone.0085001-Vu1], [@pone.0085001-Yang1], and O\'Brien et al have suggested that PCV may reduce carriage density in children [@pone.0085001-OBrien1].

Since the introduction of PCV, several studies have reported a reduction in invasive pneumococcal disease (IPD). However, this is frequently accompanied by a change in the distribution of circulating serotypes. A decrease in vaccine type (VT) IPD and an increase in non-vaccine type (NVT) IPD have been reported in America [@pone.0085001-Kaplan1], Spain [@pone.0085001-Guevara1], Canada [@pone.0085001-Kellner1] and Australia [@pone.0085001-Roche1]. In particular, serotype 19A has been isolated more frequently after the introduction of PCV 7 [@pone.0085001-Williams1]--[@pone.0085001-Fenoll1].

This review of pneumococcal carriage in sSA aims to: 1) describe the variability in carriage prevalence across countries in sSA; 2) describe the distribution of serotypes, and 3) assess the impact of pneumococcal vaccination on carriage of VT and NVT serotypes.

Methods {#s2}
=======

A comprehensive literature search strategy was developed to identify published articles describing pneumococcal carriage in sSA ([Appendix S1](#pone.0085001.s005){ref-type="supplementary-material"}). The search was conducted in December 2011 using the electronic databases MEDLINE (from 1950), EMBASE (from 1947) and African Index Medicus (AIM). To ensure the retrieval of relevant articles, the search was performed by exploring and combining medical subject headings (MeSH) and free search terms relating to carriage, nasopharyngeal, oropharyngeal, *Streptococcus pneumoniae*, serotypes, pneumococcal vaccine and specific names of the African countries. Titles and abstracts were reviewed and duplicates, non-relevant studies, and those involving streptococcal infections other than *S. pneumoniae* were excluded ([Figure 1](#pone-0085001-g001){ref-type="fig"}). The full texts of potential papers were then screened for eligibility.

![Flow chart for eligible articles.](pone.0085001.g001){#pone-0085001-g001}

Inclusion and exclusion criteria {#s2a}
--------------------------------

The review was limited to studies from countries within the sSA region that reported the prevalence of carriage with or without serotyping of the pneumococcal isolates. We used data from both hospital and community based studies that collected swabs from either the nasopharynx or oropharynx. The search was limited to human subjects but there was no restriction on the age of participants, study design or language of publication. Bibliographies of relevant papers and review papers were searched to identify articles that may have been missed in the electronic search.

Data analysis {#s2b}
-------------

Data were obtained for the following variables: prevalence of *S. pneumoniae*, country, first author, year the study was conducted (or year of publication if the study year was not reported), age of participants, number of swabs collected per individual, health of the population swabbed, rural or urban setting, and season or months of the year when the study was conducted. The data were entered in an Excel spread sheet and Stata version 12 was used for all analyses. For studies with multiple swabs per individual, only results from the first swab were included in the analysis and for those with interventions, either PCV or other interventions such as antibiotics, only the control arm was included in the analysis. To assess the impact of PCV we used data from randomised trials where PCV was the intervention. The extracted data were reviewed independently by a second reviewer who checked the data to ensure completeness using the template prepared for data extraction.

To describe the prevalence of carriage by age, the studies were grouped as: \<5 years (children), 5--15 years (children), and \>15 years (adults). Studies that recruited children in both age groups were assigned to the age group 5--15 years. Studies where participants were recruited across child and adult age groups, and where suitable stratified results were unavailable were excluded from the analysis of carriage by age. A random-effects model was used to summarise carriage by age group across the different studies. Studies where the standard error of the prevalence could not be computed were excluded from this analysis. The effects of region, season and urban/rural location on carriage were examined by comparing between studies using random effects model (meta-regression). For each study that reported carriage by gender, the absolute difference in prevalence between males and females (risk difference) was calculated and statistical significance was determined using Fisher\'s exact test.

Data from four of the studies were pooled to assess the impact of PCV on overall carriage and the carriage of VT and NVT serotypes among children 9 to 24 months. In all four studies children who received no PCV were compared with children who received at least three doses of PCV. Random effects models were used to estimate the average effect of PCV (DerSimonian-Laird estimate) across studies and to assess the degree of heterogeneity between studies.

Serotypes isolated in each study were ranked in order of prevalence and the five most prevalent serotypes in each study were identified. For each serotype, we determined the proportion of studies in which it was among five most prevalent serotypes.

Quality of the studies {#s2c}
----------------------

The studies were reviewed for quality using the WHO guidelines for conducting nasopharyngeal studies. The guidelines are for the material used for sample collection, the technique of sample collection, and the transport media [@pone.0085001-OBrien2]. For each study, we identified potential sources of bias in the method of selection of study subjects.

Results {#s3}
=======

Characteristics of the studies {#s3a}
------------------------------

A total of 57 studies were included in this review ([Table 1](#pone-0085001-t001){ref-type="table"}). Southern Africa contributed the most studies, 23(40.3%). Twenty studies (35.1%) were from West Africa with more than half of these from The Gambia. There were 12(21.1%) and 2(3.5%) studies from East and Central Africa respectively.

10.1371/journal.pone.0085001.t001

###### Characteristics of studies included in the review (n = 32,253).

![](pone.0085001.t001){#pone-0085001-t001-1}

  First author,(ref)                                      Country                      Year                                    Age                                  Population                 Swab type    Route                    Swabs/person
  ---------------------------------------------------- -------------- -------------------------------------- --------------------------------------- ---------------------------------------- ------------ ------- -------------------------------------------------
  **Central Africa**                                                                                                                                                                                               
  Rowe, [@pone.0085001-Rowe1]                               CAR                        1995                                 2 m--58 m                  opd[a](#nt102){ref-type="table-fn"}     c.alginate    NPS                        single
  Ndip, [@pone.0085001-Ndip1]                             Cameron                      2004                                10 y--21 y                 school[b](#nt103){ref-type="table-fn"}       ns        OPS                        single
  **East Africa**                                                                                                                                                                                                  
  Ringertz, [@pone.0085001-Ringertz1]                     Ethiopia                     1987                                   \<5 y                                    comm                    c.alginate    NPS                        single
  Rusen, [@pone.0085001-Rusen1]                            Kenya                       1990                                   \<5 y                    opd[c](#nt104){ref-type="table-fn"}     c.alginate    NPS                        single
  Joloba, [@pone.0085001-Joloba1]                          Uganda                      1995                                   \<3 y                    opd[d](#nt105){ref-type="table-fn"}     c.alginate    NPS                        single
  Batt, [@pone.0085001-Batt1]                             Tanzania                     2000                                   \<7 y                                    comm                      cotton      OPS                        single
  Scott, [@pone.0085001-Scott3]                            Kenya                       2000                                   \<7 y                                 comm/hosp                    dacron      NPS                        single
  Nyandiko, [@pone.0085001-Nyandiko1]                      Kenya                       2003                                  \<42 m                    opd[e](#nt106){ref-type="table-fn"}       dacron      NPS                        single
  Abdullahi, [@pone.0085001-Abdullahi1]                    Kenya                       2004                                    all                                     comm                      rayon       NPS                         twice
  Blossom, [@pone.0085001-Blossom1]                        Uganda                      2004                                20 y--55 y                                  HIV                        BBL        OPS                        single
  Abdullahi, [@pone.0085001-Abdullahi2]                    Kenya                       2006                                   \<5 y                    opd[f](#nt107){ref-type="table-fn"}       rayon       NPS    single/multiple[g](#nt108){ref-type="table-fn"}
  Haug, [@pone.0085001-Haug1]                             Ethiopia                    2003/6                                1 y--5 y                                   comm                        ns        NPS                        single
  Skalet, [@pone.0085001-Skalet1]                         Ethiopia                     2006                                  \<10 y                                    comm                        ns        NPS                        single
  Scott, [@pone.0085001-Scott1]                            Kenya                      2004/7                                  \<1 y                                    EPI                       rayon       NPS                        single
  **Southern Africa**                                                                                                                                                                                              
  Jacobs, [@pone.0085001-Jacobs1]                       South Africa                   1977                                    all                     hosp[h](#nt109){ref-type="table-fn"}    c.alginate    NPS                        single
  Klugman, [@pone.0085001-Klugman1]                     South Africa                   1977                   \<5 y[i](#nt110){ref-type="table-fn"}                    DCC                     c.alginate    NPS                        single
  Robins-Browne, [@pone.0085001-RobinsBrowne1]          South Africa                   1981                                  \<12 y                                    hosp                    c.alginate    NPS                        single
  Oppenheim, [@pone.0085001-Oppenheim1]                 South Africa                   1983                                  \<10 y                                    hosp                    c.alginate    NPS                       multiple
  Frederiksen, [@pone.0085001-Frederiksen1]                Zambia                      1986                                  \<10 y                    opd[d](#nt105){ref-type="table-fn"}       cotton      OPS                        single
  Woolfson, [@pone.0085001-Woolfson1]                      Zambia                      1994                                   \<6 y                    opd[a](#nt102){ref-type="table-fn"}     c.alginate    NPS                        single
  Mthwalo, [@pone.0085001-Mthwalo1]                       Lesotho                      1995                                   \<5 y                                    comm                    c.alginate    NPS                        single
  Yomo, [@pone.0085001-Yomo1]                              Malawi                      1995                                   \<5 y                                    MCH                       cotton     both                       multiple
  Feikin, [@pone.0085001-Feikin1]                          Malawi                      1997                                 2 w--59 m                  opd[f](#nt107){ref-type="table-fn"}         ns        NPS                        single
  Feikin, [@pone.0085001-Feikin2]                          Malawi                      1997                                 2 w--59 m                  opd[a](#nt102){ref-type="table-fn"}         ns        NPS                       multiple
  Huebner, [@pone.0085001-Huebner1]                       Botswana                     1997                                 2 m--5 y                                 opd/ward                  c.alginate    NPS                        single
  Gordon, [@pone.0085001-Gordon1]                          Malawi                      1998                                    all                                      ns                       cotton      NPS                        single
  McNally, [@pone.0085001-McNally1]                     South Africa                   2001                                 1 m--59 m                  hosp[j](#nt111){ref-type="table-fn"}       wire       NPS                        single
  Cotton, [@pone.0085001-Cotton1]                       South Africa                   2002                                 8 w--5 y                                   HIV                        wire       NPS                        single
  Pemba, [@pone.0085001-Pemba1]                         South Africa                   2002                                  adults                                    HIV                     c.alginate   Both                         twice
  Gill, [@pone.0085001-Pemba1]                             Zambia                      2003                                 6 w--18 m                               HIV+ve/−ve                 c.alginate    NPS    single/multiple[g](#nt108){ref-type="table-fn"}
  Valles, [@pone.0085001-Valles1]                        Mozambique                    2003                                   \<5 y                                    opd                     c.alginate    NPS                        Single
  von Gottberg, [@pone.0085001-vonGottberg1]            South Africa                   2006                                    all                     hosp[k](#nt112){ref-type="table-fn"}      dacron      NPS                        single
  Mbelle, [@pone.0085001-Mbelle1]                       South Africa   1999[l](#nt113){ref-type="table-fn"}                   \<1 y                                    comm                    c.alginate    NPS                       multiple
  Huebner, [@pone.0085001-Huebner2]                     South Africa   2000[l](#nt113){ref-type="table-fn"}                 2 m--5 y                  clinic[d](#nt105){ref-type="table-fn"}   c.alginate    NPS                        single
  Mwenya, [@pone.0085001-Mwenya1]                          Zambia                      2002                                 6 m--14 y                                  HIV                       rayon       NPS                        single
  Marcus, [@pone.0085001-Marcus1]                       South Africa                   1993                                 3 m--8 y                                  school                   c.alginate    NPS                        single
  **West Africa**                                                                                                                                                                                                  
  Hansman, [@pone.0085001-Hansman1]                       Nigeria                      1977                                    ns                      opd[a](#nt102){ref-type="table-fn"}         ns        NPS                        single
  Lloyd- Evans, [@pone.0085001-LloydEvans1]                Gambia                      1989                                    all                                  comm/hosp                    cotton      NPS    single/multiple[g](#nt108){ref-type="table-fn"}
  Obaro, [@pone.0085001-Obaro2]                            Gambia                      1995                                    2 y                                     comm                        ns        NPS                        single
  Denno, [@pone.0085001-Denno1]                            Ghana                       1996                                   \<1 y                    opd[e](#nt106){ref-type="table-fn"}        wire       NPS                        single
  Kacou-Ndouba, [@pone.0085001-KacouNDouba1]            Ivory Coast                    1997                                   \<5 y                                    EPI                     c.alginate    NPS                        single
  Obaro, [@pone.0085001-Obaro1]                            Gambia                      2000                                   \<1 y                                    EPI                       cotton      NPS                         twice
  Darboe, [@pone.0085001-Darboe2]                          Gambia                      2001                                    all                                     comm                    c.alginate    NPS                       multiple
  Adegbola, [@pone.0085001-Adegbola1]                      Gambia      2001[l](#nt113){ref-type="table-fn"}                  3--4 y                                    comm                    c.alginate    NPS                        single
  Hill, [@pone.0085001-Hill2]                              Gambia                     2003/4                                   all                                     comm                    c.alginate    NPS                        single
  Hill, [@pone.0085001-Hill1]                              Gambia      2008[l](#nt113){ref-type="table-fn"}                   \<1 y                                    comm                    c.alginate    NPS                       multiple
  Nwachukwu, [@pone.0085001-Nwachukwu1]                   Nigeria      2008[l](#nt113){ref-type="table-fn"}                 2 m--59 m                                  EPI                         ns        NPS                        single
  Bere, [@pone.0085001-Bere1]                           Burkina Faso                   2000                                   \<5 y                                    MCH                     c.alginate    NPS                        single
  Cheung, [@pone.0085001-Cheung1]                          Gambia                      2003                                 9 m--27 m                                  comm                        ns        NPS                       multiple
  Kandakai-Olukemi, [@pone.0085001-KandakaiOlukemi1]      Nigeria      2009[l](#nt113){ref-type="table-fn"}                15 y--25 y                                 school                     cotton      NPS                        single
  Mureithi, [@pone.0085001-Mureithi1]                      Gambia      2009[l](#nt113){ref-type="table-fn"}                19 y--50 y                                  comm                        ns        NPS                        single
  Darboe, [@pone.0085001-Darboe1]                          Gambia      2010[l](#nt113){ref-type="table-fn"}                   \<1 y                                   clinic                   c.alginate    NPS                       multiple
  Donkor, [@pone.0085001-Donkor1]                          Ghana                       2006                                  \<13 y                    hosp[m](#nt114){ref-type="table-fn"}        ns        NPS                        single
  Hill, [@pone.0085001-Hill3]                              Gambia      2010[l](#nt113){ref-type="table-fn"}                    All                                     comm                        ns        NPS                       multiple
  Kacou-N\'douba, [@pone.0085001-KacouNdouba1]          Ivory Coast    2010[l](#nt113){ref-type="table-fn"}                   \<5 y                                     ns                         ns        ns                         single
  Ota, [@pone.0085001-Ota1]                                Gambia      2011[l](#nt113){ref-type="table-fn"}                   \<1 y                                    EPI                     c.alginate    NPS                        single
  Roca, [@pone.0085001-Roca1]                              Gambia                     2006/8                                All ages                                   comm                    c.alginate    NPS                        single

Ref- reference, N-number of individuals, ns- not stated; NPS- Nasopharyngeal swab; OPS- Oropharyngeal swab; c.alginate- Calcium Alginate; w-week, m-months, y-years, comm- community, opd-outpatient department, hosp-hospital, EPI -Expanded programme on immunisation clinic, DCC- day care centre, MCH- mother & child clinic,

^a^ any illness,

^b^ with respiratory tract infection,

^c^ perinatal follow up HIV clinic used control group,

^d^ routine check or immunisation,

^e^ medical conditions as well as routine checks,

^f^ minor illnesses no hospitalisations,

^g^ some swabbed once others swabbed more than once,

^h^ children and carers sick and well,

^I^ adults also swabbed age not specified,

^j^ hosp severe pneumonia,

^k^ tuberculosis patients,

^l^ year published,

^m^ patients returning for review after minor illness.

The majority of the studies (87.7%) collected nasopharyngeal swabs, only 4(7.0%) collected oropharyngeal swabs, and 2(3.5%) studies collected both. In one study, the anatomical site of sampling was not reported. Calcium alginate was the most common type of swab 26 (45.6%). Other types used were cotton 7(12.3%), Dacron 3(5.3%), Rayon 4(7.0%), BBL 1(1.8%) and wire 3(5.3%). Thirteen studies (22.8%) did not report the type of swab that was used.

The majority of the studies (75.4%) were conducted in children, 11(19.3%) involved both children and adults and only 3(5.3%) studies exclusively recruited adults. Most studies (53.0%) were in healthy individuals, 14.0% had both healthy and sick patients, 24.5% were conducted in outpatients, 6.9% in HIV positive populations and in 1.7% the population was not stated. In 15(26.3%) studies, participants were swabbed more than once.

Pneumococcal carriage by age and geographic region {#s3b}
--------------------------------------------------

Carriage was highest for children less than 5 years and decreased with age ([Table 2](#pone-0085001-t002){ref-type="table"} and Figures S1, S2 & S3). High prevalence (\>85%) in children were recorded in Ethiopia, Mozambique (only one study) and The Gambia. The Gambia also had the highest prevalence in adults ([Table 2](#pone-0085001-t002){ref-type="table"}). The prevalence of carriage varied considerably between studies. The I^2^ index, which assesses heterogeneity between studies, was greater than 99% in all the age categories. In children less than 5 years the prevalence was higher in studies conducted in a rural, rather than urban setting. Carriage was not associated with season, population health, swab type or year ([Table 3](#pone-0085001-t003){ref-type="table"}).

10.1371/journal.pone.0085001.t002

###### Pneumococcal carriage prevalence in sub Saharan Africa by age.
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  A                                                                            
  -------------------------- ------------------ ------------ ----------------- --------------
  Hansman, 1977                   Nigeria           44.4         34.6 54.2          2.50
  Jacobs, 1977                  South Africa        41.8         37.6 45.9          2.58
  Klugman, 1977                 South Africa        58.2         54.6 61.8          2.59
  Ringertz, 1987                  Ethiopia          89.8         88.0 91.6          2.60
  Lloyd- Evans, 1989               Gambia           85.1         83.0 87.2          2.60
  Rusen, 1990                      Kenya            22.5         13.5 31.6          2.51
  Woolfson, 1994                   Zambia           71.9         66.4 77.4          2.57
  Mthwalo, 1995                   Lesotho           59.6         55.4 63.8          2.58
  Yomo, 1995                       Malawi           47.5         40.6 54.4          2.55
  Rowe, 1995                        CAR             71.2         66.8 75.6          2.58
  Joloba, 1995                     Uganda           61.8         54.9 68.7          2.55
  Obaro, 1995                      Gambia           93.8         90.1 97.5          2.59
  Denno, 1996                      Ghana            51.4         45.8 57.0          2.57
  Kacou-Ndouba, 1997            Ivory Coast         63.3         56.9 69.7          2.56
  Feikin, 1997                     Malawi           87.0         84.8 89.2          2.59
  Huebner, 1997                   Botswana          69.1         63.6 74.5          2.57
  Feikin, 1997                     Malawi           84.0         81.6 86.4          2.59
  Gordon, 1998                     Malawi           42.0         35.4 48.1          2.56
  Mbelle, 1999                  South Africa        61.0         54.8 67.2          2.56
  Huebner, 2000                 South Africa        39.9         34.4 45.4          2.57
  Obaro, 2000                      Gambia           92.1         88.4 95.8          2.59
  Bere, 2000                    Burkina Faso        50.7         47.4 54.0          2.59
  Adegbola, 2001                   Gambia           87.0         80.5 93.5          2.55
  McNally, 2001                 South Africa        47.6         42.4 52.8          2.57
  Darboe, 2001                     Gambia           81.0         73.2 88.3          2.53
  Cotton, 2002                  South Africa        22.2         16.5 27.9          2.56
  Hill, 2003                       Gambia           93.4         88.7 98.1          2.58
  Cheung, 2003                     Gambia           86.1         84.0 88.2          2.60
  Gill, 2003                       Zambia           25.8         23.6 28.1          2.59
  Nyandiko, 2003                   Kenya            35.9         25.2 46.5          2.48
  Valles, 2003                   Mozambique         87.0         83.1 90.9          2.58
  Haug, 2003                      Ethiopia          93.3         88.8 97.8          2.58
  Scott, 2004                      Kenya            78.0         73.0 83.0          2.57
  Abdullahi, 2004                  Kenya            57.0         52.4 61.6          2.58
  Abdullahi, 2006                  Kenya            76.0         65.4 86.6          2.48
  Hill, 2008                       Gambia           86.0         81.6 90.4          2.58
  Nwachukwu, 2008                 Nigeria           69.0         58.2 79.8          2.47
  Kacou-N\'douba, 2010          Ivory Coast         27.5         24.7 30.3          2.59
  Darboe, 2010                     Gambia           21.0         15.3 26.7          2.56
  ***Overall prevalence***                       ***63.2***   ***55.6 70.8***   ***100.00***
  *I^2^(%), p-value*          *99.33, \<0.001*                                 

  B                                                                             
  -------------------------- ------------------- ------------ ----------------- --------------
  Robins-Browne, 1981           South Africa         31.0         27.2 34.8          7.80
  Oppenheim, 1983               South Africa         24.5         23.0 25.9          7.85
  Frederiksen, 1986                Zambia            16.0         11.4 20.6          7.78
  Lloyd- Evans, 1989               Gambia            63.0         56.9 69.1          7.72
  Marcus, 1993                  South Africa         40.6         31.2 49.9          7.54
  Scott, 2000                       Kenya            37.0         30.2 43.8          7.88
  Batt, 2000                      Tanzania           10.7         9.0 12.4           7.85
  Mwenya, 2002                     Zambia            55.0         44.7 65.3          7.47
  Hill, 2003                       Gambia            86.3         82.5 90.1          7.80
  Abdullahi, 2004                   Kenya            41.0         36.3 45.7          7.77
  Skalet, 2006                    Ethiopia           81.7         74.8 88.6          7.68
  Donkor, 2006                      Ghana            15.3         9.0 21.6           7.71
  von Gottberg, 2007            South Africa         53.8         41.7 65.9          7.34
  ***Overall prevalence***                        ***42.6***   ***29.9 55.4***   ***100.00***
  *I^2^(%), pvalue*           *99.34, ,\<0.001*                                 

  C                                                                            
  -------------------------- ------------------ ------------ ----------------- --------------
  Klugman, 1977                 South Africa        15.4         8.2 22.5           7.75
  Jacobs, 1977                  South Africa        9.9          7.1 12.7           8.08
  Lloyd- Evans, 1989               Gambia           20.0         −0.9 40.9          5.65
  Gordon, 1998                     Malawi           10.8         8.1 13.5           8.08
  Darboe, 2001                     Gambia           13.0         8.3 17.7           7.97
  Pemba, 2002                   South Africa        8.8          6.9 10.7           8.11
  Hill, 2003                       Gambia           60.6         56.4 64.8          8.00
  Gill, 2003                       Zambia           8.8          7.3 10.3           8.13
  Blossom, 2004                    Uganda           18.0         14.9 21.1          8.07
  Abdullahi, 2004                  Kenya            6.4           4.0 8.8           8.10
  Mureithi, 2009                   Gambia           80.0         66.1 93.9          6.83
  Kandakai-Olukemi, 2009          Nigeria           42.0         31.7 52.3          7.36
  Darboe, 2010                     Gambia           78.0         72.2 83.8          7.88
  ***Overall prevalence***                       ***28.0***   ***19.0 37.0***   ***100.00***
  *I^2^(%), pvalue*           *99.00, \<0.001*                                 

\(A\) Children \<5years, n = 15,879 (B) Children 5--15 years, n = 7,180 (C) Adults \>15 years n = 5,350.

10.1371/journal.pone.0085001.t003

###### Differences in the prevalence of pneumococcal carriage in sub Saharan Africa.
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                                                     Prevalence (95%CI)                                                                                          
  ------------------------------------------------- -------------------- ------------------ ---------- ---- -------------------- ------ ---- ------------------- ------
  **Region**                                                                                                                                                     
  East                                                       8            64.5(43.5--85.5)     0.73     4     42.5(−4.2--89.2)    0.72   2    12.2(−61.5--85.9)   0.06
  Central                                                    1                  71.2                    6     36.1(19.6--52.6)           0           \-          
  Southern                                                   15           56.4(44.8--67.9)              0            \-                  5     9.3(7.8--10.9)    
  West                                                       15           68.8(55.3--82.)               3    54.9(−35.0--144.8)          6    49.3(19.2--79.3)   
  **Settlement**                                                                                                                                                 
  Rural                                                      16           80.2(70.5--89.9)   \<0.0001   5     55.7(16.1--95.3)    0.26   6     32.9(1.8--63.9)    0.44
  Urban                                                      15           53.4(45.2--61.7)              5     35.3(13.4--57.2)           4    19.5(−3.7--42.7)   
  **Season**                                                                                                                                                     
  Dry                                                        13           64.7(54.8--74.6)     0.54     5     31.4(11.4--51.3)     na    3     9.6(6.6--12.6)      na
  Rainy                                                      6            58.4(31.1--85.9)              0            \-                  0           \-          
  **Population** [a](#nt117){ref-type="table-fn"}                                                                                                                
  Well                                                       21           69.2(59.5--78.9)     0.11     8     44.3(19.1--69.5)    0.97   9    36.1(13.1--59.1)    0.33
  Sick[b](#nt118){ref-type="table-fn"}                       10           64.3(50.2--78.4)              3     35.5(−1.7--72.7)           0           \-          
  HIV                                                        1                  22.2                    1           55.0                 2    13.3(−45.1--71.7)  
  **Year** [c](#nt119){ref-type="table-fn"}                                                                                                                      
  Before 2000                                                19           63.7(54.4--72.9)     0.92     5     34.9(12.4--57.3)    0.39   4     10.8(7.7--13.8)    0.22
  After 2000                                                 20           62.8(50.4--75.3)              8     47.5(24.3--70.8)           9    34.8(11.2--58.3)   
  **Swab route**                                                                                                                                                 
  NPS                                                        37           64.6(57.1--72.2)      na      11    48.1(32.8--63.3)    0.06   11   31.2(11.9--50.5)    0.67
  OPS                                                        0                   \-                     2    13.3(−20.2--46.1)           1          18.0         
  **Swab type**                                                                                                                                                  
  WHO[d](#nt120){ref-type="table-fn"}                        21           60.9(50.5--71.3)              6     45.5(22.1--68.9)           6    22.3(−6.4--51.0)   
  Others                                                     10           59.9(44.1--75.8)     0.91     5    36.9. (8.1--65.8)    0.55   6    26.3(3.84--48.9)    0.78

na- not applicable,

^a^ excluded studies with both sick and well when prevalence was not available by category.

^b^ all illnesses including pneumonia & upper respiratory tract infections.

^c^ PCV first licensed 2000,

^d^ WHO recommended calcium alginate & Dacro; p-values and prevalences based on meta-regression; N+ = no. of studies;

Data were used from N = 55 studies. Three studies contributed data to all three age groups, five studies contributed to \<5 yrs and \>15 yrs, 31 studies contributed to \<5 yrs only, 10 studies contributed to 5--15 yrs only, and five studies contributed to \>15 yrs only. Settlement, season, population, swab route and swab type were not recorded in all studies, and for these variables we have used studies where data were available.

Pneumococcal carriage and gender {#s3c}
--------------------------------

Eleven studies reported the prevalence of carriage by gender. Three of these studies reported no association, one study reported a higher prevalence in males compared to females (p = 0.05), and one study reported a higher prevalence in females (OR = 0.61; 95% CI: 0.39--0.95; p = 0.02). From our analysis, there was no significant difference in the risk of carriage between males and females in any of the remaining six studies ([Table 4](#pone-0085001-t004){ref-type="table"}).

10.1371/journal.pone.0085001.t004

###### Prevalence of pneumococcal carriage in Africa by gender.

![](pone.0085001.t004){#pone-0085001-t004-4}

  Country                                                    Ref               Age grp    Prevalence % (n/N)        RD        95%CI     Pvalue     
  ---------------------------------------------- ---------------------------- ---------- -------------------- -------------- ------- ------------- ------
  Uganda                                           [@pone.0085001-Joloba1]     Children     62.3 (66/106)      61.2(52/85)    0.01    −0.13,0.15    0.88
  Uganda                                           [@pone.0085001-Blossom1]     Adults       25.9(28/108)      18.3(80/438)   0.08    −0.01,0.17    0.08
  South Africa[a](#nt123){ref-type="table-fn"}     [@pone.0085001-McNally1]    Children           ns                ns         \-                   0.02
  South Africa[b](#nt124){ref-type="table-fn"}      [@pone.0085001-Pemba1]      Adults       8.8(75/854)         0.0(0/2)     0.09        na        1.00
  Ghana                                             [@pone.0085001-Denno1]     Infants      47.5 (75/158)      49.7(76/153)   −0.02   −0.13, 0.09   0.73
  Nigeria                                         [@pone.0085001-Nwachukwu1]   Children        (ns/55)           (ns/45)       \-         \-        0.05
  Zambia                                          [@pone.0085001-Woolfson1]    Children     70.9 (93/131)      71.9(92/128)   −0.01   −0.12,0.10    0.88
  Kenya[a](#nt123){ref-type="table-fn"}           [@pone.0085001-Abdullahi1]   All ages           ns                ns         \-         \-         nd
  Kenya                                           [@pone.0085001-Nyandiko1]    Children      32.3(11/34)       39.5(17/43)    −0.07   −0.29,0.14    0.64
  Gambia                                            [@pone.0085001-Hill2]      All ages           ns                ns                    \-         nd
  Malawi                                            [@pone.0085001-Yomo1]      Children        48.9(ns)          46.3(ns)     0.03        \-         nd

RD- Risk difference, ns- not stated, nd-no difference reported in paper, na -- not applicable, Ref-reference,

^a^ OR = 0.61 (95% CI: 0.39, 0.95),

^b^ HIV infected mineworkers 99.8% male, p-value based on Fisher\'s exact test.

PCV and pneumococcal carriage {#s3d}
-----------------------------

Seven studies from three countries (The Gambia, Kenya and South Africa) assessed the association between PCV and carriage. One study from the Gambia was a village cluster randomised trial with adults and older children in 10 villages receiving one dose of PCV 7, and adults and older children in 11 control villages receiving meningococcal serogroup C vaccine. In both arms of the trial, infants aged between 2 and 11 months received three doses of the vaccine given at monthly intervals, and children aged between 12 and 30 months received two doses at one month interval between doses. Infants born during the study received three doses of the vaccine given monthly at the ages 2, 3, and 4 months [@pone.0085001-Roca1]. The other six studies compared carriage in vaccinated and unvaccinated children using data from individually randomised control trials (RCTs). Four of these studies collected carriage data on all children that participated in the trial [@pone.0085001-Obaro1]--[@pone.0085001-Mbelle1] while two studies used data from a subsample of children enrolled in the original trial [@pone.0085001-Cheung1], [@pone.0085001-Obaro2] ([Table 5](#pone-0085001-t005){ref-type="table"}).

10.1371/journal.pone.0085001.t005

###### Studies of pneumococcal conjugate vaccination and carriage in Africa (n = 9,549).

![](pone.0085001.t005){#pone-0085001-t005-5}

                                                                                                                                                                                                                                 Trial arm n/N (%)                                                                         
  --------------------------------------------- -------- ----------- ------------------------------------- ------------------- ---------------------------------------- ----------------------------------------- ----------------------------------------------- ----------------------------------------------- -------- ---------
  SK Obaro                                        1995     Gambia                    PCV 5                      2, 3,4 w                                                                                                           **PCV^3+1^**                                     **Control**                            
                                                                                      PPV                         18 m                                                                                                                                                                                                     
                                                                      RCT[a](#nt126){ref-type="table-fn"}                                        24 m                                    Overall                                    22/26(84.6)                                    150/160(93.8)                   −0.09     0.112
                                                                                                                                                                                           VT                                       13/26(50.0)                                    144/160(90.0)                   −0.40    \<0.001
                                                                                                                                                                                           NVT                                      20/26(76.9)                                    68/160(42.5)                     0.34     0.001
  N.Mbelle                                        1999    S. Africa                  PCV 9                     6, 10,14 w                                                                                                           **PCV^3^**                                      **Control**                            
                                                                                      RCT                                                        6 w                                     Overall                                   64/250(25.6)                                    74/250(29.6)                    −0.04     0.368
                                                                                                                                                 10 w                                    Overall                                   110/249(44.2)                                   109/249(43.8)                   0.004     1.000
                                                                                                                                                 14 w                                    Overall                                   115/246(46.7)                                   127/247(51.4)                   −0.05     0.322
                                                                                                                                                 9 m                                     Overall                                   130/242(53.7)                                   145/239(60.7)                   −0.07     0.140
                                                                                                                                                                           VT[d](#nt129){ref-type="table-fn"}                      43/242(17.8)                                    86/239(36.0)                    −0.18    \<0.001
                                                                                                                                                                                           NVT                                     87/242(36.0)                                    59/239(24.7)                     0.11     0.008
  SK Obaro                                        2000     Gambia                    PCV 9                      2, 3, 4 m                                                                                                           **PCV^3^**                                      **Control**                            
                                                                                      RCT                                                        5 m                                     Overall                                   92/100(92.0)                                    94/102 (92.2)                   −0.002    1.000
                                                                                                                                                                                           VT                                      54/100(54.0)                                    64/102 (62.7)                   −0.09     0.253
                                                                                                                                                                                           NVT                                     45/100 (45.0)                                   33/102 (32.4)                    0.13     0.083
                                                                                                                                                 9 m                                     Overall                                   83/98 (84.7)                                     87/99(87.9)                    −0.03     0.541
                                                                                                                                                                                           VT                                       61/98(62.2)                                     74/99(74.7)                    −0.13     0.067
                                                                                                                                                                                           NVT                                      28/98(28.6)                                     16/99(16.2)                     0.12     0.041
  YB.Cheung                                       2003     Gambia                    PCV 9                      2, 3, 4 m                                                                                                           **PCV^3^**                                      **Control**                            
                                                                                    nested                                                     9--15 m                                   Overall                                  943/1078(87.5)                                  914/1061(86.1)                    0.01     0.371
                                                                                    Cohort,                                                                                                VT                                     237/1051(22.5)                                  416/1041(40.0)                   −0.17    \<0.001
                                                                                      RCT                                                                                                  NVT                                    449/1051(42.7)                                  280/1041(26.9)                    0.16    \<0.001
                                                                                                                                               21--27 m                                  Overall                                   793/967(82.0)                                   813/961(84.6)                   −0.03     0.143
                                                                                                                                                                                           VT                                      230/922(24.9)                                   381/925(41.2)                   −0.16    \<0.001
                                                                                                                                                                                           NVT                                     373/922(40.5)                                   242/925(26.2)                    0.14    \<0.001
  J. A Scott[\*](#nt135){ref-type="table-fn"}    2004/7     Kenya                    PCV 7                  0 or 6 & 10, 14 w                                                                                      **PCV^3+1^** [e](#nt130){ref-type="table-fn"}   **PCV^3+1^** [f](#nt131){ref-type="table-fn"}           
                                                                                   PCV7/PPV                       36 w                           18 w                    Overall[g](#nt132){ref-type="table-fn"}                   205/263(78.0)                                        \-                                 
                                                                                      RCT                                                                                                  VT                                        ns(25.0)                                        ns(31.0)                      −0.06     0.280
                                                                                                                                                 36 w                    Overall[g](#nt132){ref-type="table-fn"}                   188/244(77.0)                                        \-                                 
                                                                                                                                                                                           NVT                                       ns(62.0)                                        ns(51.0)                       0.11     0.250
  M.Ota[\*](#nt135){ref-type="table-fn"}          2011     Gambia                    PCV 7                      2, 3, 4 m                                                                                                          **PCV^3+1^**                                    **PCV^1+1^**                            
                                                                                      PPV                         10 m                           5 m                                     Overall                                   177/215(82.3)                                   178/217(82.0)                   0.003     1.000
                                                                                      RCT                                                                                                  VT                                      29/215(13.5)                                    43/217(19.8)                    −0.06     0.093
                                                                                                                                                                                           NVT                                     151/215(70.2)                                   138/217(63.6)                    0.07     0.153
                                                                                                                                                 11 m                                    Overall                                   143/200(71.5)                                   155/203(76.4)                   −0.05     0.307
                                                                                                                                                                                           VT                                      20/200(10.0)                                    41/203(20.2)                    −0.10     0.005
                                                                                                                                                                                           NVT                                     123/200(61.5)                                   117/203(57.6)                    0.04     0.478
                                                                                                                                                 15 m                                    Overall                                   159/194(82.0)                                   181/205(88.3)                   −0.06     0.090
                                                                                                                                                                                           VT                                      24/194(12.4)                                    38/205(18.5)                    −0.06     0.098
                                                                                                                                                                                           NVT                                     136/194(70.1)                                   149/205(72.7)                   −0.03     0.581
  A.Roca[\*](#nt135){ref-type="table-fn"}        2003/8    Gambia                    PCV 7                      All ages                                                                                                            **PCV^1^**                                      C**ontrol**                            
                                                                                   clustered                                    2--5 y[h](#nt133){ref-type="table-fn"}                   Overall                                    79/90(87.8)                                     53/59(89.8)                    −0.02     0.796
                                                                                      RCT                                                                                                  VT                                       18/90(20.0)                                     17/59(28.8)                    −0.09     0.239
                                                                                                                                                                                           NVT                                      61/90(67.6)                                     39/59(66.1)                     0.02     0.860
                                                                                                                                2--5 y[i](#nt134){ref-type="table-fn"}                   Overall                                    23/30(76.7)                                     30/38(78.9)                    −0.02     1.000
                                                                                                                                                                                           VT                                       4/30(13.3)                                      9/38(23.7)                     −0.10     0.360
                                                                                                                                                                                           NVT                                     19/30(63. 6)                                     23/38(60.5)                     0.03     1.000

w-weeks, m-months, y-years, RD- Risk difference- Risk in the PCV vaccinated group minus the risk in the control group calculated in Stata, PPV-Polyvalent polysaccharide vaccine, ns- not stated,

^a^ children who received PCV 5 in an RCT and controls matched with age and place of residence who did not receive PCV, PCV^b+c^ received b+c doses of PCV doses with

^b^ for the primary series and

^c^ for booster dose,

^d^ includes vaccine associated serotypes.

^e^ received PCV7 at 6, 10 and 14 weeks,

^f^ received PCV7 at 6, 10 and 14 weeks or at 0, 10 and 14 weeks,

^g^ Overall carriage for both groups,

^h^ 4--6 months after vaccination,

^i^ 22 months after vaccination;

these three studies were not included in the meta-analysis (in these 3 studies, both groups received PCV).P-value obtained using Fisher\'s exact test.

The participants in all the PCV studies were children from the general population presenting at infant welfare clinics for immunisation, except for the village cluster randomized trial which recruited children and adults in the community. Carriage of vaccine type (VT) serotypes was reduced by vaccination, while carriage of non-vaccine type serotypes was greater among vaccinated children ([Figure 2](#pone-0085001-g002){ref-type="fig"} & [Table 5](#pone-0085001-t005){ref-type="table"}). The prevalence of overall carriage was not affected by vaccination.

![A comparison of pneumococcal carriage in vaccinated and unvaccinated children aged 9--24 months.\
A positive risk difference indicates higher prevalence in the vaccinated arm.](pone.0085001.g002){#pone-0085001-g002}

Pneumococcal carriage serotypes in Africa {#s3e}
-----------------------------------------

Twenty eight (49.1%) of the studies had collected data on serotypes and in total 6904 isolates were serotyped in these studies. The seven studies with PCV intervention were excluded from this analysis. There were 70 serotypes and serogroups. Serotype 19F was among the five most prevalent serotypes in 14/21 studies, serotype 6B in 13/21, serotype 14 in 13/21, serotype 6A in 11/21 and serotype 23F in 9/21 studies. Some studies only described serogroups, and in these studies serogroups 19 and 6 were the most common. In the PCV 9 vaccine trial in South Africa, serotypes 6B, 19F and 23F were the most common vaccine serotypes in both vaccinated (6B 3.3%, 19F 7.8%, 23F 2.9%) and control (6B 11.7%, 19F 13.4%, 23F 5.8%) groups, and serotype 6B and 19F were significantly less frequent in the PCV 9 vaccinated children. 15 (9.1%), 6A (5.8%) and 19A (2.9%) were the most common NVT serotypes/serogroup in the vaccinees, with serogroup 15 significantly increased in vaccinated compared to control children (9.1% versus 3.8%, p value 0.017) [@pone.0085001-Mbelle1].

In The Gambia, the carriage study during the PCV 9 trial found that serotype 19F (11.5%) was again the most common VT serotype isolated and serogroup 15 was the most common NVT, and more prevalent in the PCV 9 vaccinated children (11.8% versus 8.5%, P\<0.05). When the study children were swabbed a second time about 10 months later, NVT serotypes 10, 21 and 35B were isolated more frequently from PCV 9 vaccinated children than controls. There was no longer any difference between the groups for carriage of serotype 19F [@pone.0085001-Cheung1]. In the cluster randomised trial conducted in The Gambia, serotypes 23F, 6A, 6B, 3, 11 and 7C were the most common serotypes before vaccination and serotypes 3, 11, 19F and 6A were the most common serotypes after vaccination [@pone.0085001-Roca1].

Discussion {#s4}
==========

This systematic review of pneumococcal carriage in sSA summarises the prevalence of carriage, distribution of serotypes and the effect of PCV on carriage. The majority of the studies were from Southern and West Africa, particularly South Africa and the Gambia. There were only two studies from Central Africa.

We found that the prevalence of pneumococcal carriage in sSA is generally high but there is much variation between countries, particularly among older age groups. Carriage was higher in children than adults as reported outside sSA [@pone.0085001-Robinson1], [@pone.0085001-Trotter1].

A small number of studies conducted outside sSA have reported a higher prevalence of carriage in males compared to females [@pone.0085001-Millar1]--[@pone.0085001-Scott2]. However, in this review gender was not associated with carriage in 9/11 studies, and in two studies carriage was more common among females [@pone.0085001-McNally1], [@pone.0085001-Nwachukwu1]. One of these studies was conducted in South Africa among children 1--59 months with severe pneumonia, 67.3% of whom were HIV positive and another was in Nigeria in children 1--4 years who presented for regular check-up or immunisation, some of whom had a cough and a cold.

The five serotypes that were most common in this review are among the seven that cause most global IPD in children; PCV 10 and PCV 13 will cover at least 70% of the cases of IPD caused by these serotypes [@pone.0085001-Johnson1], [@pone.0085001-Publication1]. The other two serotypes, serotypes 1 and 5, are rarely isolated from carriage studies, although they are often associated with pneumococcal disease epidemics [@pone.0085001-Dagan1]--[@pone.0085001-SmithVaughan1]. Serotypes also differ in their ability to cause invasive pneumococcal disease [@pone.0085001-Brueggemann1].

It has been suggested that the impact of PCV on disease can be determined by pneumococcal carriage studies because it is newly acquired serotypes that lead to disease [@pone.0085001-Gray2]. In this review, studies that assessed the impact of PCV on carriage generally showed a decrease in carriage of VT and an increase in NVT serotypes, with no change in the overall prevalence of carriage. One study in this review, and one in native Indians have shown a gradual decrease in overall carriage following vaccination [@pone.0085001-Roca1], [@pone.0085001-Scott2]. Continuous surveillance of circulating serotypes will be important as countries introduce PCV.

Nasopharyngeal swabs are more sensitive for *S.pneumoniae* than the oral swabs [@pone.0085001-Capeding1], [@pone.0085001-Pemba1]. The prevalence of carriage is therefore likely to be underestimated in the four studies that used oral swabs. The different lab methods used might also have been responsible for some of the variability in the prevalence of carriage reported in this review. WHO recommends calcium alginate or Dacron polyester swabs since cotton swabs suppress the pneumococcus [@pone.0085001-OBrien2]. However, only half of the studies (50.9%) followed the WHO guidelines, and in 13 (22.4%) the type of swab was not stated.

Another source of variation between studies is the prevalence of antibiotic use, since antibiotics might reduce carriage [@pone.0085001-Varon1]. Some studies excluded those individuals who had taken antibiotics from their analysis. However, even when these individuals were excluded, often different periods were used to define prior use.

We have combined results from all available published studies irrespective of the study population (unpublished studies were not included in this review). Study participants were recruited from the community, day care centres, schools and outpatient clinics and hospital wards. Hospital patients may have higher carriage than the rest of the population, particularly if they were admitted for pneumonia. Generally, we expect selection bias to be less in studies conducted in the community compared with studies that use outpatient clinics. In this review, 57.9% of the studies were conducted in hospital/clinic settings and 35.1% of the studies in the community.

We have summarised available data on pneumococcal carriage in sub Saharan Africa. There remain unexplained differences in carriage within the region, and multi centre studies may provide reasons for some of the differences seen. Pneumococcal carriage studies can show indirect effects of PCV by showing changes in unvaccinated age groups and can supplement disease surveillance studies as PCV is introduced in the region.
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